AstraZeneca, GSK reiterate 2020 outlook; Shanghai biotech I-Mab is looking for a US partner — report
→ The coronavirus pandemic may have thrown off the predictability of what the rest of 2020 will bring for most industries, and indeed many drugmakers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
